Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%
A Non-Interventional Study on the Tolerability and Efficacy of Octagam 5% or 10% or panzyga. Patients with any indication (replacement and immonomodulation) as prescribed by the treating physician. Marketed Octagam 5% or 10% or panzyga will be used according to the investigator prescription; intravenous (iv) administration.The primary objective is to detect and evaluate adverse drug reactions (ADRs) occurring during or after the administration of Octagam or panzyga in any indication, age group or treatment regimen, where a causal relationship to the administration of Octagam or panzyga is suspected.
Study Type
OBSERVATIONAL
Enrollment
344
Octagam IVIG 5% or 10%
Panzyga
Adverse Drug Reactions
Number of patients with adverse drug reactions
Time frame: up to one year
Infection Occurrence
Pool of PID/SID Patients: Influence of IVIG/SCIG Treatment. Frequency, intensity, and duration of infectious episodes assessed. At the last available assessment, the influence of study IVIG on the frequency, intensity, and duration of the infections.
Time frame: Up to one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Octapharma Research Site
Gmunden, Austria
Octapharma Research Site
Graz, Austria
Octapharma Research Site
Klagenfurt, Austria
Octapharma Research Site
Oberndorf, Austria
Octapharma Research Site
Salzburg, Austria
Octapharma Research Site
Vienna, Austria
St. Paul's Hospital
Vancouver, British Columbia, Canada
Health Sciences Centre
Winnipeg, Manitoba, Canada
Hamilton Health Sciences
Hamilton, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
...and 28 more locations